EMPA-KIDNEY (The Study of Heart and Kidney Protection With Empagliflozin)

Inclusion Criteria: * Age ≥18 years or at "full age" as required by local regulation * Evidence of chronic kidney disease at risk of kidney disease progression defined by at least 3 months before and at the time of Screening Visit * CKD-EPI eGFR ≥20 to \<45 mL/min/1.73m² or * CKD-EPI eGFR ≥45 to \<90 mL/min/1.73m² with urinary albumin:creatinine ratio ≥200 mg/g (or protein:creatinine ratio ≥300 mg/g); * Clinically appropriate doses of single agent RAS-inhibition with either ACEi or ARB unless such treatment is either not tolerated or not indicated * A local Investigator judges that the participant neither requires empagliflozin (or any other SGLT-2 or SGLT-1/2 inhibitor), nor that such treatment is inappropriate; Key Exclusion Criteria: * Currently receiving SGLT-2 or SGLT-1/2 inhibitor * Diabetes mellitus type 2 and prior atherosclerotic cardiovascular disease with an eGFR \>60 mL/min/1.73m2 at Screening * Receiving combined ACEi and ARB treatment * Maintenance dialysis, functioning kidney transplant, or scheduled living donor transplant * Polycystic kidney disease * Previous or scheduled bariatric surgery * Ketoacidosis in the past 5 years * Symptomatic hypotension, or systolic blood pressure \<90 or \>180 mmHg at Screening * ALT or AST \>3x ULN at Screening * Hypersensitivity to empagliflozin or other SGLT-2 inhibitor * Any intravenous immunosuppression therapy in last 3 months; or anyone currently on \>45 mg prednisolone (or equivalent) * Use of an investigational…